AR054438A1 - Inhibidores de adn -pk - Google Patents
Inhibidores de adn -pkInfo
- Publication number
- AR054438A1 AR054438A1 ARP060101479A ARP060101479A AR054438A1 AR 054438 A1 AR054438 A1 AR 054438A1 AR P060101479 A ARP060101479 A AR P060101479A AR P060101479 A ARP060101479 A AR P060101479A AR 054438 A1 AR054438 A1 AR 054438A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- alkyl
- attached
- hydrogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67183005P | 2005-04-15 | 2005-04-15 | |
| US67188605P | 2005-04-15 | 2005-04-15 | |
| GB0507831A GB0507831D0 (en) | 2005-04-18 | 2005-04-18 | DNA-PK inhibitors |
| US69606405P | 2005-07-01 | 2005-07-01 | |
| US71890405P | 2005-09-20 | 2005-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054438A1 true AR054438A1 (es) | 2007-06-27 |
Family
ID=36579227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101480A AR053358A1 (es) | 2005-04-15 | 2006-04-12 | Inhibidores de adn - pk |
| ARP060101479A AR054438A1 (es) | 2005-04-15 | 2006-04-12 | Inhibidores de adn -pk |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101480A AR053358A1 (es) | 2005-04-15 | 2006-04-12 | Inhibidores de adn - pk |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7696203B2 (https=) |
| EP (2) | EP1869021A1 (https=) |
| JP (2) | JP2008535903A (https=) |
| KR (1) | KR20080002963A (https=) |
| AR (2) | AR053358A1 (https=) |
| AU (1) | AU2006235731A1 (https=) |
| CA (1) | CA2603637A1 (https=) |
| IL (1) | IL186445A0 (https=) |
| MX (1) | MX2007012696A (https=) |
| NO (1) | NO20075809L (https=) |
| TW (2) | TW200720274A (https=) |
| UY (1) | UY29479A1 (https=) |
| WO (2) | WO2006109084A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| AU2004265149A1 (en) * | 2003-08-13 | 2005-02-24 | Kudos Pharmaceuticals Limited | Aminopyrones and their use as ATM inhibitors |
| BRPI0515498A (pt) * | 2004-09-20 | 2008-07-29 | Kudos Pharm Ltd | inibidores de dna-pk |
| EP1848712A1 (en) * | 2005-02-09 | 2007-10-31 | Kudos Pharmaceuticals Ltd | Atm inhibitors |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| UY31232A1 (es) * | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
| EP2198710A1 (de) | 2008-12-19 | 2010-06-23 | Bayer CropScience AG | Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze |
| WO2010136778A1 (en) * | 2009-05-29 | 2010-12-02 | Kudos Pharmaceuticals Limited | Dibenzothiophene derivatives as dna- pk inhibitors |
| FR2947550B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| HUE034503T2 (en) | 2009-07-02 | 2018-02-28 | Sanofi Sa | 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine |
| CN102482286B (zh) | 2009-07-02 | 2015-07-15 | 赛诺菲 | 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途 |
| WO2011001115A1 (fr) | 2009-07-02 | 2011-01-06 | Sanofi-Aventis | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb ) |
| SG10201402867TA (en) | 2009-07-02 | 2014-08-28 | Sanofi Sa | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
| FR2947548B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| FR2951170B1 (fr) * | 2009-10-09 | 2011-12-02 | Sanofi Aventis | Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| FR2947551B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| EP2558290B1 (en) | 2010-04-15 | 2019-01-23 | 3M Innovative Properties Company | Retroreflective articles including optically active areas and optically inactive areas |
| WO2011137428A1 (en) * | 2010-04-30 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating hiv infection: inhibition of dna dependent protein kinase |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| DK2655375T3 (en) | 2010-12-23 | 2015-03-09 | Sanofi Sa | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF |
| US9133168B2 (en) | 2010-12-28 | 2015-09-15 | Sanofi | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
| UY34013A (es) * | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ?compuestos de cromenona con actividad anti-tumoral?. |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| CA2876539A1 (en) * | 2012-06-15 | 2013-12-19 | Basf Se | Multicomponent crystals comprising dasatinib and selected co-crystal formers |
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| CA2968090A1 (en) * | 2014-12-02 | 2016-06-09 | Prana Biotechnology Limited | 4h-pyrido[1,2-a]pyrimidin-4-one compounds |
| EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS |
| CN109232476B (zh) * | 2018-11-06 | 2020-06-26 | 常州大学 | 一种制备n-苯基-3-吗啡啉丙酰胺的方法 |
| US20230111712A1 (en) * | 2020-03-13 | 2023-04-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stable reactive compositions for bioconjugation, probes, and protein labeling |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1303724A (https=) | 1969-05-14 | 1973-01-17 | ||
| JPH0753725B2 (ja) | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| AU634994B2 (en) | 1988-12-21 | 1993-03-11 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| JPH03215423A (ja) | 1990-01-18 | 1991-09-20 | Kyowa Hakko Kogyo Co Ltd | 血管拡張剤 |
| EP0525123B1 (en) | 1990-06-20 | 1997-09-17 | PHARMACIA & UPJOHN COMPANY | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| ATE128128T1 (de) | 1990-06-29 | 1995-10-15 | Upjohn Co | Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one. |
| US5252735A (en) * | 1990-06-29 | 1993-10-12 | The Upjohn Company | Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones |
| US5302613A (en) * | 1990-06-29 | 1994-04-12 | The Upjohn Company | Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones |
| WO1994005283A1 (fr) | 1992-09-02 | 1994-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Medicament anti-vih |
| EP0695547B1 (en) | 1993-04-09 | 2001-08-08 | Toyama Chemical Co., Ltd. | Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases |
| US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| US5441947A (en) | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
| US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
| US5504103A (en) | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
| CA2133815A1 (en) | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
| US6632789B1 (en) | 1994-04-29 | 2003-10-14 | The United States Of America As Represented By The Secretary Of The Navy | Methods for modulating T cell responses by manipulating intracellular signal transduction |
| US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
| GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| AU1461197A (en) | 1995-11-16 | 1997-06-05 | Icos Corporation | Cell cycle checkpoint pik-related kinase materials and methods |
| GB2302021A (en) | 1996-10-16 | 1997-01-08 | Lilly Co Eli | Inhibiting bone loss or resorption |
| WO1998055602A1 (en) | 1997-06-06 | 1998-12-10 | Mayo Foundation For Medical Education And Research | Screening for phosphatidylinositol related-kinase inhibitors |
| WO1998056391A1 (en) | 1997-06-13 | 1998-12-17 | President And Fellows Of Harvard College | Methods for treating human cancers |
| FR2776291B1 (fr) | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
| US6348311B1 (en) * | 1999-02-10 | 2002-02-19 | St. Jude Childre's Research Hospital | ATM kinase modulation for screening and therapies |
| US6387640B1 (en) * | 1999-02-10 | 2002-05-14 | St. Jude Children's Research Hospital | ATM kinase modulation for screening and therapies |
| US6333180B1 (en) * | 1999-12-21 | 2001-12-25 | International Flavors & Fragrances Inc. | Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate |
| CN1891693A (zh) | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
| JP2004501191A (ja) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
| WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| DE60203260T2 (de) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB0119863D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| AU2002357667A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| US7049313B2 (en) | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| BR0307944A (pt) | 2002-02-25 | 2005-02-01 | Kudos Pharm Ltd | Piranonas úteis como inibidores de atm |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| AU2004265149A1 (en) * | 2003-08-13 | 2005-02-24 | Kudos Pharmaceuticals Limited | Aminopyrones and their use as ATM inhibitors |
| BRPI0515498A (pt) * | 2004-09-20 | 2008-07-29 | Kudos Pharm Ltd | inibidores de dna-pk |
| EP1848712A1 (en) * | 2005-02-09 | 2007-10-31 | Kudos Pharmaceuticals Ltd | Atm inhibitors |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| UY31232A1 (es) | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones |
-
2006
- 2006-04-12 AR ARP060101480A patent/AR053358A1/es not_active Application Discontinuation
- 2006-04-12 AR ARP060101479A patent/AR054438A1/es not_active Application Discontinuation
- 2006-04-13 JP JP2008505966A patent/JP2008535903A/ja active Pending
- 2006-04-13 KR KR1020077026502A patent/KR20080002963A/ko not_active Withdrawn
- 2006-04-13 US US11/403,606 patent/US7696203B2/en not_active Expired - Fee Related
- 2006-04-13 CA CA002603637A patent/CA2603637A1/en not_active Abandoned
- 2006-04-13 EP EP06726768A patent/EP1869021A1/en not_active Withdrawn
- 2006-04-13 US US11/403,763 patent/US20060264623A1/en not_active Abandoned
- 2006-04-13 WO PCT/GB2006/001379 patent/WO2006109084A1/en not_active Ceased
- 2006-04-13 WO PCT/GB2006/001369 patent/WO2006109081A1/en not_active Ceased
- 2006-04-13 EP EP06726777A patent/EP1869040A1/en not_active Withdrawn
- 2006-04-13 MX MX2007012696A patent/MX2007012696A/es not_active Application Discontinuation
- 2006-04-13 AU AU2006235731A patent/AU2006235731A1/en not_active Abandoned
- 2006-04-13 JP JP2008505964A patent/JP2008535902A/ja active Pending
- 2006-04-14 TW TW095113561A patent/TW200720274A/zh unknown
- 2006-04-14 TW TW095113560A patent/TW200720271A/zh unknown
- 2006-04-18 UY UY29479A patent/UY29479A1/es not_active Application Discontinuation
-
2007
- 2007-10-07 IL IL186445A patent/IL186445A0/en unknown
- 2007-11-12 NO NO20075809A patent/NO20075809L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008535902A (ja) | 2008-09-04 |
| IL186445A0 (en) | 2008-01-20 |
| MX2007012696A (es) | 2008-03-14 |
| TW200720274A (en) | 2007-06-01 |
| AR053358A1 (es) | 2007-05-02 |
| AU2006235731A1 (en) | 2006-10-19 |
| CA2603637A1 (en) | 2006-10-19 |
| EP1869021A1 (en) | 2007-12-26 |
| US20060264623A1 (en) | 2006-11-23 |
| JP2008535903A (ja) | 2008-09-04 |
| KR20080002963A (ko) | 2008-01-04 |
| US20060264427A1 (en) | 2006-11-23 |
| EP1869040A1 (en) | 2007-12-26 |
| US7696203B2 (en) | 2010-04-13 |
| NO20075809L (no) | 2007-12-27 |
| TW200720271A (en) | 2007-06-01 |
| WO2006109084A1 (en) | 2006-10-19 |
| WO2006109081A1 (en) | 2006-10-19 |
| UY29479A1 (es) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054438A1 (es) | Inhibidores de adn -pk | |
| CR11546A (es) | Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica | |
| TW200738706A (en) | Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors | |
| ECSP099728A (es) | Compuestos amino-heterocíclicos | |
| NI200700102A (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
| AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
| EA200702080A1 (ru) | Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич | |
| AR062786A1 (es) | Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos. | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| CR10712A (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales | |
| DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
| GT200500368A (es) | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios | |
| AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| PE20060459A1 (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| TW200718422A (en) | 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | |
| AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
| PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |